33.23
2.50%
0.81
プレマーケット:
33.23
前日終値:
$32.42
開ける:
$32.95
24時間の取引高:
560.64K
Relative Volume:
0.69
時価総額:
$1.89B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.9252
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-6.18%
6か月 パフォーマンス:
-28.71%
1年 パフォーマンス:
+52.92%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
33.23 | 1.89B | 32.87M | 674.31M | -330.11M | 11.36 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
2023-02-03 | 開始されました | Piper Sandler | Overweight |
2022-11-17 | アップグレード | Goldman | Sell → Neutral |
2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-12-03 | 開始されました | BofA Securities | Buy |
2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
2021-07-01 | 開始されました | Raymond James | Mkt Perform |
2021-06-10 | 開始されました | H.C. Wainwright | Buy |
2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-05-23 | 再開されました | Goldman | Neutral |
2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
2018-05-23 | 開始されました | Citigroup | Buy |
2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
2018-02-15 | 繰り返されました | Needham | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-08-10 | 繰り返されました | Needham | Buy |
2017-08-08 | 繰り返されました | SunTrust | Buy |
2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2017-06-26 | ダウングレード | Janney | Buy → Neutral |
2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
2016-10-24 | 開始されました | Needham | Buy |
2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat
Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey
Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN
Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times
Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN
Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times
FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat
Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada
Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com
FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter
FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria
FDA approves label update for Agios's PYRUKYND - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Objective long/short (AGIO) Report - Stock Traders Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9%Should You Sell? - MarketBeat
Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times
Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):